Calcium channel blocker use and risk of Parkinson's disease

Mov Disord. 2010 Sep 15;25(12):1818-22. doi: 10.1002/mds.23191.

Abstract

We investigated whether the use of calcium channel blockers (CCBs) was associated with a reduced risk of Parkinson's disease (PD) in two large prospective cohorts: the Nurses' Health Study (NHS) and Health Professionals' Follow-Up Study (HPFS). Cox proportional hazards models were used to estimate relative risks (RRs) and 95% confidence intervals (CIs) to assess the association between use of CCBs and risk of PD adjusting for potential confounders. We identified 514 incident cases of PD during follow-up. No association between baseline use of CCBs (RR = 1.18, 95% CI: 0.73-1.92), frequency of use or duration of use of CCBs and PD risk was observed (P > 0.2 for all). These findings do not support a role for CCBs in providing neuroprotection against development of PD.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural

MeSH terms

  • Calcium Channel Blockers / therapeutic use*
  • Female
  • Humans
  • Hypertension / drug therapy*
  • Male
  • Nurses
  • Parkinson Disease / etiology*
  • Proportional Hazards Models
  • Risk

Substances

  • Calcium Channel Blockers